{"entity":{"id":"nct04421963","kind":"trial","name":"Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib","aka":["ROSY-O"],"tldr":"A phase 3 trial of Olaparib in ovarian cancer, run by AstraZeneca, active and no longer recruiting.","summary":"Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib is a phase 3 interventional study registered as NCT04421963 by AstraZeneca, with 185 participants enrolled, started 2020-08-04 and due to reach its primary completion in 2027-04-06. Interventions recorded: Olaparib. Conditions listed: Ovarian Cancer, Breast Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04421963","url":"https://clinicaltrials.gov/study/NCT04421963"}],"tags":["ctgov-ingest"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":["parp-inhibitor"],"targets":[],"drugs":["olaparib"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04421963","phase":"3","setting":"Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib and Are Judged by the Investigator to Clinically Benefit From Continued Treatment","sponsor":"AstraZeneca","started":"2020-08-04","startedType":"actual","enrolled":185,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04421963/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"technology":[{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"}],"drug":[{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}